Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Arcturus Appoints Chairman, Reinstates CEO & COO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Arcturus Appoints Chairman, Reinstates CEO & COO

Dr. Peter Farrell has been named as chairman of the Board of Directors, Joseph E. Payne & Dr. Pad Chivukula reinstated

By: Betsy Louda

, Contract Pharma

Arcturus Therapeutics announced that Dr. Peter Farrell has been named as chairman of the Board of Directors of the Company.  Additionally, Joseph E. Payne has been reinstated as president and chief executive officer, and Dr. Pad Chivukula has been reinstated as chief scientific officer and chief operating officer.


“I am extremely pleased to resume my role as President and CEO of Arcturus,” stated Joseph Payne. “With the litigation behind us, the team is 100% committed to developing our pipeline of novel RNA therapeutics, to strengthening and advancing all of our pharmaceutical partnerships and to creating value for our shareholders.”  

“I am delighted to be named Chairman of Arcturus,” said Dr. Peter Farrell, “I believe that the proprietary chemistry and drug delivery platforms developed by Arcturus set it apart from its peers and provide significant competitive advantages.  I look forward to working with the team over the coming years to build a world class RNA medicines company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters